Gildan beats Q1 estimates, maintains full-year guidance By Investing.com

Gildan reported Q1 adjusted EPS of $0.43, beating consensus by $0.04, and record revenue of $1.17 billion versus $1.15 billion expected, up 63.8% year over year. The strong top-line growth was driven by the HanesBrands acquisition, though GAAP diluted EPS from continuing operations was -$0.30 due to a $106.3 million inventory fair value step-up charge. Management kept full-year 2026 guidance unchanged at $6.0 billion-$6.2 billion in revenue and $4.20-$4.40 adjusted EPS, while reaffirming synergy targets from the integration.

Analysis

The important read-through is not that the company beat, but that the market is being asked to underwrite a multi-year integration story while near-term margins are still being diluted by mix and SG&A normalization. That creates a classic “good numbers, bad stock” setup: the operating quality of the base business is obscured by acquisition accounting, and investors will likely discount headline EPS until synergies become visible in quarterly cadence rather than management commentary.

The second-order winner is the debt/cost-reset optionality embedded in the combined platform. If integration stays on track, the market may rerate the company on forward free cash flow rather than current margin optics, which should also pressure smaller branded apparel competitors and private-label suppliers that lack scale. The main loser is any short-duration capital that bought the deal for instant accretion; they now face a longer validation window, with the first real catalyst likely being the next two quarters of gross margin and working-capital improvement rather than the current print.

The contrarian point is that consensus may be underestimating how quickly synergy capture can show up in the P&L once procurement, distribution, and overhead are rationalized. If the company delivers even a modest beat on the implied Q2 margin guide, the market could flip from “integration skepticism” to “earnings revision” mode, especially because the forward numbers are still close enough to estimates that there is room for upward drift. The risk is that retail/wholesale channel mix turns less favorable again and the synergy ramp slips into late 2026, which would turn this into a dead-money name for months.

Key Decisions for Investors

• Go long GIL on a 3-6 month horizon only on weakness near post-print support; target a rerating to forward FCF multiple expansion if Q2 confirms margin stabilization, with a stop if gross margin fails to improve sequentially.
• Pair trade: long GIL / short HBI for a 1-2 quarter window. The combined-company execution path is more likely to create visible earnings power than a standalone turnaround at the acquired asset, while HBI faces the burden of proving it can remain relevant outside the roll-up.
• Sell downside protection on GIL only after the next earnings call if management reiterates the synergy cadence and working capital improves; use cash-secured puts to monetize elevated integration uncertainty.
• Avoid chasing the move in the next 1-2 weeks; the cleaner entry is after the market tests whether the Q2 margin guide is credible. If the stock gaps down on initial skepticism, that is the higher-probability add point.
• For event-driven exposure, consider a tight-dated call spread in GIL into the next quarterly print, sized modestly, as the setup is asymmetric if management converts guidance into visible margin expansion.